Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) EBIT Margin (2021 - 2024)

Amylyx Pharmaceuticals (AMLX) has 4 years of EBIT Margin data on record, last reported at 784.02% in Q4 2024.

  • For Q4 2024, EBIT Margin fell 78581.0% year-over-year to 784.02%; the TTM value through Sep 2025 reached 349.68%, down 21260.0%, while the annual FY2024 figure was 72.6%, 8279.0% down from the prior year.
  • EBIT Margin reached 784.02% in Q4 2024 per AMLX's latest filing, up from 18187.74% in the prior quarter.
  • Across five years, EBIT Margin topped out at 20.9% in Q3 2023 and bottomed at 18187.74% in Q3 2024.
  • Average EBIT Margin over 4 years is 4069.77%, with a median of 203.76% recorded in 2022.
  • Peak YoY movement for EBIT Margin: skyrocketed 1001743bps in 2023, then plummeted -1820864bps in 2024.
  • A 4-year view of EBIT Margin shows it stood at 8041.4% in 2021, then skyrocketed by 97bps to 203.76% in 2022, then soared by 101bps to 1.78% in 2023, then plummeted by -44064bps to 784.02% in 2024.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 784.02% in Q4 2024, 18187.74% in Q3 2024, and 7457.09% in Q2 2024.